Introduction
Increasing bacterial resistance to macrolides and β-lactams amongst respiratory pathogens has limited their clinical usefulness, [1] [2] [3] and created a market for the development of quinolones with enhanced activity against pneumococci and atypical respiratory pathogens. These newer fluoroquinolones are now recommended in several guidelines for the treatment of community-acquired pneumonia. [4] [5] [6] [7] Some evidence of resistance to these new antimicrobials and reports of clinical treatment failures have already emerged, [8] [9] [10] [11] although resistance remains at a low level. The search for superior fluoroquinolone preparations continues.
ABT-492 is 1-(6-amino-3,5-difluoropyridine-2-yl)-8-chloro-6-fluoro-(3-hydroxyyazetide-1-yl)-4-oxo-1,4-dihydroquinolone-3-carboxy acid (A-319492), currently being developed by Abbott Laboratories. Preliminary data indicate that it has a broad spectrum of activity rivalling that of other newer fluoroquinolones, with increased potency against multidrug-resistant bacteria (Abbott data on file). In this study, the in vitro activity of ABT-492 was compared with two β-lactams (including co-amoxiclav at a 2:1 ratio), a ketolide and five fluoroquinolones against isolates including those with a known mechanism of resistance. The effects of human serum and of raising the inoculum concentration were also investigated. The activity of ABT-492 was compared with that of ciprofloxacin and erythromycin against three isolates of Chlamydia trachomatis and one strain of Chlamydia pneumoniae.
Materials and methods

Antimicrobials
The antibiotics used in this study were ABT-492 and erythromycin (Abbott Laboratories, IL, USA), telithromycin (Aventis Pharma, Romainville, France), ciprofloxacin and moxifloxacin (Bayer AG, Wuppertal, Germany), levofloxacin (Aventis Ltd, Uxbridge, UK), gatifloxacin (Grunenthal GmbH, Aachen, Germany), amoxicillin, clavulanic acid and gemifloxacin (GlaxoSmithKline, Worthing, UK). Storage and preparation of agents were in accordance with the manufacturers' instructions.
Isolates
A total of 1146 isolates were studied, the majority of which were recent clinical isolates from City Hospital, Birmingham. Of the organisms with known mechanisms of resistance, 19 Streptococcus pneumoniae had reduced susceptibility to penicillin [high-level resistance (HLR) MIC ≥ 2 mg/L and intermediate-level resistance (LLR) MIC 0.12-1 mg/L] and eight with reduced susceptibility to the fluoroquinolones (including four isolates with a Ser-79→Tyr mutation in parC, two isolates with a Ser-79→Tyr mutation in parC and either a Glu-87→Lys or Glu-83→Tyr mutation in gyrA 12, 13 and two recent fluoroquinolone-resistant clinical isolates); 25 methicillin-resistant Staphylococcus aureus (MRSA); 33 vancomycin-resistant enterococci (VRE); eight imipenem-resistant Pseudomonas aeruginosa; 19 ciprofloxacin-resistant Escherichia coli; nine Neisseria gonorrhoeae with reduced susceptibility to quinolones (no zone of inhibition with a 30 µg nalidixic acid disc) and one isolate of Haemophilus influenzae with reduced susceptibility to the quinolones [quinolone resistance determining region (QRDR) mutation in gyrA Ser-84→Phe and no zone of inhibition with a 30 µg nalidixic acid disc]. 14 The following control strains were tested, E. coli ATCC 25922 and NCTC 10418, P. aeruginosa ATCC 27853 and NCTC 10662, Enterococcus faecalis ATCC 29212, H. influenzae NCTC 11931, S. pneumoniae ATCC 49619, N. gonorrhoeae NCTC 12700, Bacteroides fragilis NCTC 9343 and S. aureus NCTC 6571, ATCC 25923 and ATCC 29213.
Susceptibility testing
The MIC was determined by British Society for Antimicrobial Chemotherapy (BSAC) methodology. 15 Briefly, Iso-Sensitest agar (Oxoid, Basingstoke, UK) supplemented where necessary with 5% defibrinated horse blood (TCS, Bodolph Clayton, UK) and 20 mg/L NAD (SigmaAldrich Co. Ltd, Poole, UK) for fastidious organisms or 50 mg/L 1-(4-nitro-phenyl)-glycerol (PNPG; BDH, Poole, UK) to prevent swarming. Plates were incubated for 18-20 h at 35-37°C in air or for fastidious organisms in an atmosphere of 4-6% CO 2 . In the case of anaerobes, Brucella agar (Oxoid) supplemented with 5% lysed horse blood was used and incubation was in an atmosphere of 10% CO 2 /10% H 2 /80% N 2 . A final inoculum of 10 4 cfu/spot was delivered using a multipoint inoculator (Mast, Bootle, UK). The MIC was defined as the lowest concentration of antimicrobial inhibiting bacterial growth, one or two colonies being ignored. To determine the effect of inoculum on the MIC, 163 isolates were each tested at an inoculum of 10 4 and 10 6 cfu/spot.
Effect of human serum
MICs and MBCs of ABT-492 were determined for two isolates each of E. coli, P. aeruginosa, S. pneumoniae, and Moraxella catarrhalis in the presence of human serum (TCS) as previously described. 15 The basal medium, Iso-Sensitest broth (Oxoid), was supplemented with 5% laked horse blood (Oxoid) where necessary and either 0%, 20% or 70% human serum which had been screened for the presence of blood-borne viruses (HBsAg, HCV, HIV-1 and HIV-2). An inoculum of approximately 5 × 10 5 cfu/mL was used for testing. For broths with equivocal or no growth, 50 µL was subcultured onto blood agar and incubated under the appropriate conditions for 18-20 h. The MBC was defined as the lowest concentration of antibiotic giving a growth of less than 25 colonies on subculture (99.9% kill).
Chlamydia susceptibility testing
MICs and minimum lethal concentrations (MLCs) of ABT-492, ciprofloxacin and erythromycin were determined for four chlamydia isolates (C. pneumoniae TW183, C. trachomatis L2, C. trachomatis CT 599, C. trachomatis CT 527), using a previously described technique. 16 Briefly, McCoy cell coverslip cultures were inoculated to form a monolayer of approximately 1 × 10 3 inclusion forming units per coverslip and doubling dilutions of the antibiotics added. Eagle's minimum essential medium with Earle's salts (Invitrogen Ltd, UK) was used in place of antibiotic for the positive control. Plates were incubated at 35-37°C for 48 h in 4-6% CO 2 and stained with an immunofluorescent reagent (Dako Diagnostics, Ely, UK). The MIC was defined as the lowest concentration of antimicrobial to inhibit development of inclusions and the MLC as the lowest concentration at which no proper inclusions were formed after a further 48 h in antibiotic-free medium.
Analysis of data
For the control strains, MICs were compared with expected values. 15 Test MICs were evaluated with reference to existing BSAC breakpoints 15 and where in sufficient numbers to allow comparison, with regard to the 'wild-type' population as defined by the Swedish Reference Group for Antibiotics (SRGA). 17 The population with reduced susceptibility to fluoroquinolones was identified by reference to the ciprofloxacin MICs.
Results
For control strains, MICs were within the acceptable range. The overall activity of ABT-492 compared with the other antibiotics is shown in Table 1, while Table 2 compares MICs for the 'wild-type' population with those possessing a mechanism of resistance to the fluoroquinolones and Table 3 the activity of ABT-492, ciprofloxacin and erythromycin against Chlamydia spp.
ABT-492 MIC 90 s were less than or equal to that of ciprofloxacin and the newer fluoroquinolones (moxifloxacin, levofloxacin, gemifloxacin, gatifloxacin) for all isolates of Enterobacteriaceae, but ciprofloxacin MICs were lower for Proteus mirabilis, Proteus vulgaris, Morganella morganii and Providencia rettgeri. Ciprofloxacin MIC 90 s for E. coli were raised as a whole, as there were a number of highly ciprofloxacin-resistant strains included in the collection and MIC 90 s for the newer fluoroquinolones were also raised (MIC 90 ≥8 mg/L), but ABT-492 less so (MIC 90 2 mg/L). Nineteen ciprofloxacin-resistant E. coli strains all had MICs at or above the breakpoint for the newer fluoroquinolones, except one strain that was susceptible to gatifloxacin, but ABT-492 MICs were amongst the lowest and four strains had MICs ≤ 1 mg/L. However, amongst the 'non wild-type' population, the MIC 50 and MIC 90 for ABT-492 were raised 64-and 128-fold, respectively (Table 2) . ABT-492 was the most active fluoroquinolone against the anaerobes tested.
P. aeruginosa MIC 90 results were higher for ABT-492 than ciprofloxacin and gatifloxacin, but equal to levofloxacin, moxifloxacin and gemifloxacin. MIC 90 results for ABT-492 were raised in the 'non wild-type' compared with the 'wild-type' populations, 0.5 and 64 mg/L, respectively. ABT-492 was the most active agent against all staphylococci tested, but a higher MIC 90 was observed for MRSA (0.5 mg/L) compared with methicillin-susceptible S. aureus (MSSA) (0.008 mg/L). ABT-492 was also the most active agent against the 'Streptococcus milleri group' and the most active quinolone against group B streptococci. It shared equal highest quinolone activity with gemifloxacin for the group A streptococci tested. ABT-492 was equally active against penicillin-susceptible and -resistant pneumococci (data not shown). For the ciprofloxacin-resistant pneumococci (MIC 90 128 mg/L), ABT-492 was superior in activity to the other quinolones tested (MICs ≤ 0.03 mg/L).
ABT-492 was 2-to 8-fold and 4-to 32-fold more active than the newer fluoroquinolones against Enterococcus faecium and E. faecalis, respectively, although this was offset by an eight-fold increase in MIC 90 amongst the ciprofloxacin-resistant strains. It was 4-to 128-fold more active against vancomycin-resistant E. faecalis (MIC 90 Increasing the inoculum from 10 4 to 10 6 cfu/spot raised the MIC ≤ 2-fold for most isolates, but greater differences were observed for three S. aureus (8-to 16-fold), one S. pneumoniae (8-fold), one E. faecium (8-fold), four Klebsiella spp. (16-to 64-fold) and three E. coli (32-fold) ( Table 4 ).
The addition of human serum at 20% and 70% raised the MIC ≤ 4-fold for E. coli and P. aeruginosa isolates, whereas MIC results were indeterminable for S. pneumoniae and M. catarrhalis, as a result of clouding of the medium. MBCs, in the presence of 70% serum, were raised four-fold or more for seven of eight isolates investigated (Table 5) . 
Discussion
The study shows that ABT-492 has a broad spectrum of activity against Gram-negative, Gram-positive and anaerobic bacteria and therefore has several potentially useful clinical roles. The compound displayed potent activity against all of the Enterobacteriaceae investigated, although ciprofloxacin was two-fold more active for Proteus and Providencia spp. and 16-fold more active against M. morganii isolates. Most Enterobacteriaceae with pre-existing mechanisms of ciprofloxacin resistance showed increased ABT-492 MICs, but to a lesser degree. Increasing levels of ciprofloxacin resistance amongst Pseudomonas spp. have been well-documented 18 and greatly restrict clinical treatment options. Ciprofloxacin and gatifloxacin were the most active agents against P. aeruginosa and increased ABT-492 MICs were demonstrated in organisms where ciprofloxacin resistance already existed, suggesting that this new agent would not be a suitable alternative treatment option.
ABT-492 showed superior activity to ciprofloxacin against C. trachomatis, with MICs lower than those quoted previously for levofloxacin, moxifloxacin, gatifloxacin and gemifloxacin (MIC 90 s 1, 0.12, 0.25 and 0.06 mg/L, respectively) against Chlamydia spp. 19 It also showed superior activity against N. gonorrhoeae including those isolates with reduced susceptibility to fluoroquinolones. This indicates a role in the treatment of genitourinary infection, but future clinical application may be limited where resistance mechanisms already exist. ABT-492 could have an important role as a single agent in the treatment of community-acquired pneumonia, particularly where β-lactam and macrolide-resistant pathogens predominate. Activity against respiratory pathogens appeared superior to the ketolide, telithromycin, whose spectrum of activity includes pneumococci with reduced penicillin and erythromycin susceptibility. It was the most active agent against C. pneumoniae, H. influenzae (including the one isolate with reduced susceptibility to fluoroquinolones), M. catarrhalis and S. pneumoniae including LLR and HLR isolates. Indeed, pneumococci with existing mechanisms of fluoroquinolone resistance appeared susceptible to ABT-492. Although the chlamydia isolates were not tested against a range of fluoroquinolones, the ABT-492 MIC of the C. pneumoniae isolate (0.03 mg/L) was lower than the MIC ranges reported elsewhere for levofloxacin, moxifloxacin and gemifloxacin (0.5, 0.06-0.1 and 0.06-0.12 mg/L, respectively), supporting its use as an effective agent against this pathogen. 20, 21 Anti-staphylococcal activity of ABT-492 was superior for all species tested, with good activity displayed against MRSA strains (MIC 90 0.25 mg/L). However, the relative increase in MIC 90 (>64-fold) for MRSA compared with MSSA organisms remains a concern, and highlights potential limitations in its clinical use against these resistant pathogens. Amongst the fluoroquinolones, ABT-492 showed superior activity against enterococci and, in particular, vancomycin-resistant E. faecalis including vancomycin-resistant isolates.
An inoculum effect (defined as a ≥8-fold rise in MIC at a higher inoculum compared with a lower inoculum) was observed for 10 isolates including one each of S. aureus, E. faecium, Enterobacter aerogenes, three E. coli and four Klebsiella spp. (Table 4) .
The MBC of ABT-492 was equal to or only two-fold higher than the MIC for five of six strains tested (two E. coli, two P. aeruginosa, one S. pneumoniae), and four-fold greater for one S. pneumoniae isolate. This implies that, at least in vitro, ABT-492 has a bactericidal action like existing fluoroquinolones. Although the addition of 70% human serum had little effect on the MICs, it had a marked effect on the MBCs causing a greater than or equal to four-fold increase in most cases. As the drug is 84% protein bound in humans (Abbott data), tissue distribution may be reduced in comparison with less highly bound fluoroquinolones 22 and together with the inoculum effect this will need to be reflected in the setting of breakpoints.
This in vitro study indicates that ABT-492 could play an important role in the treatment of both Gram-positive and Gram-negative infections, including those due to multi-resistant bacteria, and atypical respiratory pathogens. However, the clinical significance of the evidence indicating the existence of resistance mechanisms, as well as an observed inoculum effect and of moderately high serum protein binding are unclear and the outcome of clinical studies, including 
